Real-World Management of Retinal Vascular Diseases

This episode, titled “Real-World Management of Retinal Vascular Diseases,” features panelists discussing how retina specialists evaluate anti-VEGF treatment response and apply clinical trial data within the realities of routine practice for patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The expert faculty examine the practical clinical factors used to determine whether therapy is effectively controlling disease activity, including retinal anatomy, visual acuity, and patient-reported symptoms.

The panel highlights how fluid resolution, recurrence of exudation, and symptom progression help guide treatment adjustments and dosing interval decisions over time. The discussion emphasizes that treatment decisions are individualized, balancing imaging findings with patient function and quality of vision rather than relying on a single metric alone. The expert faculty also explore how some patients may remain symptomatic even before fluid recurrence becomes apparent, reinforcing the importance of ongoing patient communication and monitoring.

In addition, the panel examines how real-world treatment patterns compare with outcomes observed in Phase III clinical trials. The discussion explores why real-world durability and dosing intervals may differ from trial expectations due to patient variability, treatment adherence, and differences between controlled study protocols and everyday clinical practice. The panelists also address how direct-to-consumer messaging around extended dosing intervals can shape patient expectations and influence treatment conversations. Throughout the episode, the expert faculty emphasize the importance of translating clinical trial evidence into individualized care strategies that safely optimize durability, maintain visual outcomes, and reduce treatment burden for patients living with retinal vascular diseases.

Our next episode, “Access and Evidence Gaps in Retinal Vascular Diseases,” panelists will discuss how extended dosing intervals and treatment durability may influence healthcare resource utilization, treatment burden, and therapy selection in retinal vascular diseases. The expert faculty will also highlight ongoing evidence gaps, including the need for comparative durability data and future therapies targeting additional biologic pathways.